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Background: Colorectal cancer is strongly associated with lipid metabolism. NPC1L1, a sterol transporter, plays a
key role in modulating lipid homeostasis in vivo. Its inhibitor, ezetimibe, began to be used clinically to lower
cholesterol and this caused the great debate on its role in causing carcinogenesis. Here we explored the role of
NPC1L1 in colorectal tumorigenesis.
Methods: Wild-type mice and NPC1L1−/− (NPC1L1 knockout) mice were treated with azoxymethane (AOM)-dextran
sodium sulfate (DSS) to induce colitis-associated colorectal tumorigenesis. Mice were sacrificed 10, 15, 18 or 20 weeks
after AOM treatment, respectively. Colorectal tumors were counted and analyzed. Plasma lipid concentrations were
measured using enzymatic reagent kit. Protein expression level was assayed by western blot.
Results: NPC1L1−/− mice significantly had fewer tumors than wild-type. The ratio of malignant/tumor in NPC1L1−/−
mice was significantly lower than in wild-type 20 weeks after AOM-DSS treatment. NPC1L1 was highly expressed in the
small intestine of wild-type mice but its expression was undetectable in colorectal mucous membranes or tumors in
either group. NPC1L1 knockout decreased plasma total cholesterol and phospholipid. NPC1L1−/− mice had significant
lower intestinal inflammation scores and expressed inflammatory markers p-c-Jun, p-ERK and Caspase-1 p20 lower than
wild-type. NPC1L1 knockout also reduced lymphadenectasis what may be caused by inflammation. NPC1L1 knockout
in mice decreased β-catenin in tumors and regulated TGF-β and p-gp in adjacent colons or tumors. There was not
detectable change of p53 by NPC1L1 knockout.
Conclusions: Our results provide the first evidence that NPC1L1 knockout protects against colitis-associated
tumorigenesis. NPC1L1 knockout decreasing plasma lipid, especially cholesterol, to reduce inflammation and
decreasing β-catenin, p-c-Jun and p-ERK may be involved in the mechanism.
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Cancer is a major public health problem worldwide,
causing 1 in 4 deaths in the United States [1]. Colorectal
cancer (CRC) ranks as the third highest incidence and
mortality rates among men and women [1].
Evidence is accumulating that lipid metabolism is
strongly associated with cancer, including CRC [1-4]. About
11% of CRC cases have been attributed to overweight and
obesity in Europe. On the other hand, obesity is associated* Correspondence: hjmlovelx@hotmail.com
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High serum triglyceride (TG) and total cholesterol (TC), es-
pecially low-density lipoprotein cholesterol (LDL-C), are
significantly and positively associated with cancer (includ-
ing CRC) [1-4].
Serum lipid is modulated by many factors, including
some genes, such as leptin, adipose triglyceride lipase
and so on. Among these genes, Niemann-Pick C1 like 1
(NPC1L1) has been proven to be one of the most im-
portant sterol transporters [5]. It was reported that it
plays a role in modulation of lipid homeostasis, includ-
ing TG, phospholipid (PL), low-density lipoprotein,
high-density lipoprotein, and most of all, cholesterol, in
mice [6-8]. In clinic, NPC1L1 genotype was found to be
significantly associated with plasma lipid concentration,is an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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ezetimibe, began to be used in clinic to lower cholesterol
and has caused the great debate on its role in cancer.
Dr. Rossebo reported that using ezetimibe with simva-
statin to lower serum lipid caused a significant increase
of new cancer incidents [6]. Dr. Peto disputed that ana-
lyses of cancer data from several ezetimibe trials did not
provide credible evidence of adverse effect on rates of
cancer [7].
Here, we explored the role of NPC1L1 in colorectal
tumorigenesis in vivo by using transgenic mice. Our re-




NPC1L1−/− mice were described previously [8,9]. Wild-
type (WT) mice and NPC1L1−/− mice were derived from
NPC1L1+/− mice with a pure C57BL/6 background and
housed in a specific pathogen-free animal facility in plas-
tic cages in a temperature controlled room (22°C) with a
daylight cycle from 6 AM to 6 PM. Mice had free access
to a standard laboratory rodent chow diet (Rodent NIH-
07 22.5-5; Zeigler Bros Inc., Gardners, USA) and water.
All animal procedures were approved by the Institu-
tional Animal Care and Use Committee at University of
Maryland Health Sciences.
AOM-DSS induced colitis-associated tumorigenesis
AOM-DSS induced colorectal tumorigenesis was de-
scribed previously [10,11]. Six to seven week-old, male
mice were given a single intraperitoneal injection of
10 mg/kg body weight AOM (Sigma-aldrich, USA). Start-
ing at a week after injection, animals received DSS (MP
Biomedicals, Molecular weight was 36,000–50,000 Da.,
USA) for 7 days via free access to drinking water contain-
ing 2% DSS. The DSS water was replaced every day. Then,
mice were fed with regular water and there was not any
further treatment after DSS treatment.
Mice were sacrificed at different time points and colorec-
tums were excised. Colorectums were opened longitudin-
ally, flushed with ice-cold PBS and fixed in 10% formalin/
PBS. Then macroscopic tumors were counted and mea-
sured with a caliper. Enlarged abdominal (from sciatic, lum-
bar, para-aortic to truncus coeliacus) lymph nodes were
counted, collected and fixed in 10% formalin/PBS.
Histological analysis
10% formalin/PBS fixed colorectums and enlarged
lymph nodes were sent to Histoserv INC. (Germantown,
MD, USA) for paraffin embedding and hematoxylin and
eosin (H&E) staining. In brief, paraffin embedded sam-
ples were cut into 6 μM and stained with H&E. A path-
ologist counted the malignant tumors (including highgrade intraepithelial neoplasia and adenocarcinoma) and
benign tumors in each slide. The malignant/tumor ratio
of each slide was calculated and the average ratio of each
group was presented. Inflammation was scored on a 0–4
scale (0, normal mucosa; 1, minimal inflammation (occa-
sional scattered granulocytes and leukocytes); 2, mild in-
flammation (scattered granulocytes with occasional mild
infiltrates); 3, moderate inflammation (scattered granulo-
cytes with patchy moderate infiltrates); and 4, severe in-
flammation (multiple extensive areas with abundant
granulocytes and marked infiltrates))[12].
Plasma lipid concentrations measurement
Mice were sacrificed with isoflurane. Blood was col-
lected by inferior vena cava injection in an anticoagu-
lant tube and the tube was centrifuged at 800 g for
15 min at 4°C. Supernatant was collected as plasma.
Plasma free cholesterol (FC), PL were measured using en-
zymatic reagent kit from Wako Diagnostics (USA), TC
was measured using enzymatic reagent kit from Pointe
Scientific (USA). TG was measured using enzymatic re-
agent kit from Sigma-Aldrich (USA).
Western blot analysis
To obtain total protein, multiple tissues in RIPA Buffer
(50 mM Tris base, 150 mM NaCl, 1% Nonidet P-40,
0.25% Na-deoxycholate, 1 mM EDTA) with protease in-
hibitors (1 mM PMSF, 5 μg/ml leupeptin, 2 μg/ml pep-
statin, 4 μg/ml aprotinin) and phosphatase inhibitors
(10 mM NaF, 1 mM Na3VO4, 10 mM β-Glycerophosphate
disodium salt pentahydrate) were homogenized for 60 sec-
onds on ice. Tissue homogenates were centrifuged at
13,000 rpm for 20 minutes at 4°C and the supernatant was
collected as total cell protein.
To obtain membrane protein, colon mucous mem-
brane or colorectal tumors in Membrane Buffer (20 mM
Tris–HCl pH7.5, 2 mM MgCl2, 250 mM Sucrose) with
protease inhibitors and phosphatase inhibitors were ho-
mogenized for 60 seconds on ice. Tissue homogenates were
centrifuged at 2,000 rpm for 10 minutes at 4°C. The super-
natant was transferred to a new tube and the tube was cen-
trifuged at 110,000 g for 30 min at 4°C. The supernatant
was removed and left the tube upside down to drain for
1 minute. Then, the pellet was resuspended in Sample Buf-
fer (50 mM Tris–HCl pH8.0, 80 mM NaCl, 4 mM CaCl2,
1%(v/v) Triton X-100) with protease inhibitors and phos-
phatase inhibitors. This was membrane protein.
Protein was resolved by SDS/PAGE and blotted on
Nitrocellulose Membranes (Bio-Rad, USA) as previously
described[13]. Nitrocellulose Membranes were incubated
with specific primary antibodies overnight. After incubat-
ing with secondary antibodies, immunoreactive proteins
were visualized by the Enhanced Chemiluminescnet Sub-
strate (Pierce, USA).
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body, p-c-Jun (Ser63) antibody, p-Erk1/2 (Thr202/Tyr204)
antibody, β-actin antibody, α-tubulin antibody, HRP-
linked secondary antibody were from Cell signal Technol-
ogy (USA). Caspase-1 p20 antibody, p-gp antibody, p53
antibody was from Santa Cruz Biotechnology, Inc. (USA).
Statistics
The data shown represent the mean ± standard error.
Statistical differences between groups were analyzed by
Student’s t-test, one-way ANOVA or chi-square test. P <
0.05 was considered statistically significant.
Results
Azoxymethane (AOM)-dextran sodium sulfate (DSS)
treatment induces tumors only in colorectum
To explore colorectal tumorigenesis in vivo, the widely
used AOM-DSS model of colitis-associated colorectal
tumorigenesis was employed [10,11]. Mice were sacrificed
10, 15, 18 or 20 weeks after AOM injection, respectively
(Figure 1B). Macroscopic tumors were counted and mea-
sured. The detail information was summarized in
Figures 1, 2 and Table 1. Tumors were mainly distributed
on the distal part of colorectum, with more distal tu-
mors increasing in density (Figures 2A,B). Tumors were
not found in cecum or small intestine. With increased
time post-injection, tumors increased in numbers and
size (Figures 1C-F).
The liver, lung, spleen and kidneys of each mouse were
examined and neither tumor nor metastatic cancer was
found (Additional file 1: Figure S1E).
NPC1L1 knockout significantly decreases
colitis-associated tumorigenesis
The role of NPC1L1 in tumorigenesis was explored by
using genetic knockout mice. Western blot was used to
confirm that NPC1L1 was knockout in mice (Figures 1A).
Sex- and age-matched WT mice and NPC1L1−/− (NPC1L1
knockout) mice were administrated with AOM-DSS.
NPC1L1−/− mice significantly had fewer tumors than WT
mice (Figures 1C-F). NPC1L1−/− mice also had smaller tu-
mors but without a significance (Figures 1C-F, Table 1).
Tumor numbers per mouse of WT at 10 W, 15 W, 18 W
and 20 W were 7.29 ± 1.11, 7.86 ± 0.67, 9.17 ± 1.46 and
11.60 ± 1.05, respectively. Those of NPC1L1−/− were 2.43 ±
0.78, 4.00 ± 0.79, 6.00 ± 0.87 and 6.90 ± 0.89, respectively.
The difference of susceptibility to tumorigenesis be-
tween WT mice and NPC1L1−/− mice does not appear
to be caused by colon length because no significant dif-
ference in colon length between the two was detected
(Figure 1G).
Mice at 12 weeks and 24 months of age (including WT
and NPC1L1−/−) without any treatment were sacrificed
and did not show tumors in the colorectum, cecum, smallintestine, lung, liver, spleen or kidneys. This suggests
NPC1L1 knockout alone should not cause tumorigenesis
in those organs within 24 months.
NPC1L1−/− mice have a lower ratio of malignant
tumor/tumor than WT
Eight colorectums of 20 W mice from each group were
used to do H&E staining. All slides were examined by a
pathologist. Squamous metaplasia, infiltration of in-
flammatory cells, adenoma, high grade intraepithelial
neoplasia and adenocarcinoma were found in colorec-
tums of both WT group and NPC1L1−/− group
(Figure 2C). NPC1L1−/− mice had a significant lower ra-
tio of malignant tumor/tumor than WT (p < 0.05)
(Figure 2D). Malignant tumor/tumor ratio of WT was
33.9 ± 6.1% while that of NPC1L1−/− was 14.2 ± 2.8%.
NPC1L1 in mice colorectal mucous membranes or
colorectal tumors is undetectable by western blot
It was reported that NPC1L1 mRNA expression in both
mice colon and human colon was very low [8,14]. West-
ern blot was employed to assay NPC1L1 protein in in-
testine and colorectal tumors. At first, total proteins
from adjacent colorectal mucous membranes and tu-
mors were used and NPC1L1 signal was not detectable.
Because NPC1L1 is mainly expressed in cell membrane
[14,15], membrane proteins from adjacent colorectal
mucous membranes and tumors were blotted at last.
Small intestines were divided into 5 segments and total
protein from the second segment was used as a control.
As shown in Figure 3A, NPC1L1 was highly expressed in
the jejunum of WT mice and was not detectable in that of
the NPC1L1−/− mice. NPC1L1 signal was not detectable
in tumors or adjacent colorectal mucous membranes in ei-
ther group. To confirm this result, western blot membrane
was over exposed and the result was the same.
To confirm the quality of membrane protein, mem-
brane protein loading control α-tubulin and membrane
protein E-cadherin were both detected on the same mem-
brane. As shown in Figure 3A, α-tubulin and E-cadherin
were easily detected by western blot. N-cadherin was also
assayed. It was easily detected in total protein of the je-
junum and was undetectable in tumors or adjacent colo-
rectal mucous membranes (Figure 3A).
NPC1L1 knockout decreases plasma lipid, especially TC
NPC1L1 plays a key role in modulating lipid homeosta-
sis in vivo and serum lipid are reported to promote colo-
rectal tumorigenesis [2-4,8,15,16]. Therefore, plasma
lipids were assayed (Figure 3B).
Plasma TC concentration of NPC1L1−/−, as expected,
was much lower than that of WT. TC concentration of
NPC1L1−/− group without any treatment was 992 ± 82























































































































Figure 1 NPC1L1 knockout protects mice against colitis-associated tumorigenesis. (A) NPC1L1 protein expression was absent in the small
intestine 2/5 of NPC1L1−/− mice by western blot analysis. (B) Colorectal tumorigenesis was induced by injection of the procarcinogen AOM
followed by one round of DSS exposure to elicit colitis. WT mice and NPC1L1−/− mice were sacrificed at 10 weeks (10 W), 15 weeks (15 W),
18 weeks (15 W) or 20 weeks (20 W) after AOM injection, respectively. (C-F) Tumors were measured and divided into four groups according
to the maximum diameter (Group 1: ≤4 mm; Group 2: >4 mm but ≤7 mm; Group 3: >7 mm but ≤10 mm; Group 4: >10 mm). Tumor number
of each group and total tumor number distribution was diagrammed. With increased time post-injection, tumors increased in numbers and size.
NPC1L1−/− mice had fewer tumors than WT mice. **p < 0.01, #p = 0.095 compared to WT. (G) When mice were sacrificed, colorectums (The cecum was
not included.) were measured. There was not any significant difference in colon length between NPC1L1−/− mice and WT mice at any time points.
He et al. BMC Cancer  (2015) 15:189 Page 4 of 90.05). At week 10, plasma TC concentration of
NPC1L1−/− group (1047 ± 75 ug/ml) was significantly
lower than that of WT group (1377 ± 68 ug/ml) (p <
0.01). At week 20, NPC1L1−/− mice had a lower concen-
tration of TC (1113 ± 59 ug/ml) compared to WT mice
(1239 ± 91 ug/ml), but without significance (p > 0.05).
NPC1L1−/− mice had a lower FC than WT mice only
at week 10, where there was a significant difference (p <
0.05). Plasma FC concentrations of NPC1L1−/− mice
without treatment, at week 10 and week 20 were 416 ± 41
ug/ml, 359 ± 35 ug/ml and 373 ± 19 ug/ml, respectively. FC
concentrations of WT mice were 534 ± 35 ug/ml, 547 ± 59
ug/ml and 422 ± 39 ug/ml, respectively.
Untreated NPC1L1−/− mice and mice treated at week
20 had a similar TG to WT mice (p > 0.05). TG concen-
trations of WT mice without treatment, at week 20 were
1123 ± 79 ug/ml and 921 ± 49 ug/ml, respectively. TG
concentrations of NPC1L1−/− mice were 976 ± 69 ug/ml
and 932 ± 64 ug/ml, respectively. At week 10, NPC1L1−/−mice had a lower TG (799 ± 48 ug/ml) than WT mice
(1210 ± 95 ug/ml) (p < 0.01).
NPC1L1−/− mice had lower plasma PL than WT mice.
The plasma PL concentration of NPC1L1−/− group without
any treatment was 3379 ± 322 ug/ml while that of WT mice
was 4892 ± 294 ug/ml (p < 0.05). At week 10, plasma PL
concentration of NPC1L1−/− group was 3798 ± 163 ug/ml
while plasma PL concentration of WT group was 4801 ±
243 ug/ml (p < 0.01). At week 20, plasma PL concentration
of NPC1L1−/− group was 4081 ± 116 ug/ml while that of
WTgroup was 4380 ± 327 ug/ml (p > 0.05).NPC1L1 knockout reduces sensitivity to inflammatory agent
It is reported that lipid promotes colitis-associated tumori-
genesis through inflammation in mice [16]. Degrees of in-
testinal inflammation were evaluated for each group.
Intestinal inflammation scores were 3.6 ± 0.2 in WT and































Figure 2 Pathological changes. (A) Colons were excised 10 weeks after AOM injection (left) and were longitudinally opened (right). (B) Colons
were excised 20 weeks after AOM injection and were stained with H&E. (C) Squamous metaplasia, adenoma, high grade intraepithelial neoplasia
and adenocarcinoma were found in WT group and NPC1L1−/− group. (Scale bars represent 400 μm.) (D) NPC1L1−/− mice had a lower ratio of
malignant tumor/tumor than WT mice. *p < 0.05.
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inflammatory markers and are involved in carcinogenesis
[17-22]. Therefore, p-c-Jun, p-ERK and Caspase-1 p20
protein expression in tumors were assayed by western
blot. NPC1L1 knockout significantly and dramatically
decreased p-c-Jun. Both p-ERK and Caspase-1 p20 were
also decreased (Figure 3D).Table 1 Number of mice with tumors
≥10 mm ≥7 mm ≥4 mm With tumor Total
10 W WT 2 4 6 7 7
NPC1L1−/− 0 0 2 6 7
15 W WT 1 6 7 7 7
NPC1L1−/− 0 2 5 7 7
18 W WT 1 5 6 6 6
NPC1L1−/− 0 3 7 7 7
20 W WT 5 9 10 10 10
NPC1L1−/− 2 8 10 10 10NPC1L1 knockout decreases lymphadenectasis
Inflammation and cancer metastasis are two main causes
in lymphadenectasis [23,24]. In this study, enlarged ab-
dominal lymph nodes were examined (Figures 3E,F and
Table 2). Lymph nodes H&E staining showed that no
metastatic cancer was found (Figure 3F). This led to the
hypothesis that enlarged abdominal lymph nodes may be
caused by inflammation. The number of enlarged ab-
dominal lymph nodes in WT mice was higher than that
found in NPC1L1−/− mice (Figure 3E and Table 2). At
week 10, all seven WT mice had enlarged abdominal
lymph node and 5 mice had more than one. Three of
the 7 NPC1L1−/− mice had enlarged lymph nodes and
none of them had more than one. The WT group had
1.9 ± 0.3 enlarged lymph nodes per mouse and the
NPC1L1−/− group had 0.4 ± 0.2 (p < 0.01). At week 20,
all WT mice had enlarged lymph node and 9 of the 10
mice had more than one while 8 of the 10 NPC1L1−/−
mice had enlarged lymph nodes and only 2 mice had
more than one. The WT group had 2.6 ± 0.3 enlarged
Table 2 Number of mice with enlarged lymph nodes
Number of enlarged lymph Nodes 4 3 2 1 0 Total P value
10 W WT 0 1 4 2 0 7 0.001
NPC1L1−/− 0 0 0 3 4 7
15 W WT 0 0 5 2 0 7 0.08
NPC1L1−/− 0 1 0 3 3 7
18 W WT 1 1 3 1 0 6 0.08
NPC1L1−/− 0 1 1 4 1 7
20 W WT 2 3 4 1 0 10 0.004
NPC1L1−/− 0 0 2 6 2 10
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Figure 3 NPC1L1 knockout decreasing plasma lipid and reducing inflammatory sensitivity may be involved in the mechanism.
(A) Western blot. Total proteins from small intestines and membrane proteins from adjacent colon mucous membranes or tumors were blotted.
NPC1L1 in mice colorectal mucous membranes or colorectal tumors was undetectable by western blot. Membrane protein loading control
α-tubulin and membrane protein E-cadherin were easily detected in tumors or adjacent colorectal mucous membranes. N-cadherin was easily
detected in small intestine tissues while it was undetectable in tumors or adjacent colorectal mucous membranes. (B) Plasma samples from 12 W
old mice without any treatment (control), 10 W or 20 W after AOM injection were assayed for FC, TC, TG and PL. *p < 0.05, **p < 0.01. (C) The intestinal
inflammation scores of NPC1L1−/− mice were significantly lower than those of WT mice. *p < 0.05. (D) Western blot. NPC1L1 ablation decreased
inflammatory markers p-c-Jun, p-ERK and Caspase-1 p20 in tumors. (E) Fresh enlarged (sciatic and lumbar) lymph nodes. Mice were sacrificed 20 weeks
after AOM injection. (F) H&E staining of enlarged lymph nodes showed that metastasis was not found. (Scale bars represent 400 μm).
He et al. BMC Cancer  (2015) 15:189 Page 6 of 9lymph nodes while the NPC1L1−/− group only had 1.0 ±
0.2 (p < 0.01).
The effect of NPC1L1 knockout on β-catenin/p53/TGF-β/
p-gp in colitis-associated tumorigenesis was evaluated
To explore the possible involved pathways, western blot
was employed to assay β-catenin/p53/TGF-β/p-gp. The
specific protein expression level in adjacent colons and
tumors was measured on the same membrane.
β-catenin was much higher in tumors than in adjacent
colons in both groups. NPC1L1 knockout significantly de-
creased β-catenin expression level in tumors but no
changes were detected in adjacent colons (Figures 4A,B).
NPC1L1 knockout in mice didn’t detectably change p53
expression in tumors or adjacent colons (Figures 4A,B).
He et al. BMC Cancer  (2015) 15:189 Page 7 of 9Interestingly, NPC1L1 knockout dramatically increased
active TGF-β in tumors but dramatically decreased it in
adjacent colons. On the contrary, NPC1L1 knockout de-
creased TGF-β precursor in tumors and increased it in ad-
jacent colons (Figures 4 C, D).
NPC1L1 knockout in mice dramatically increased p-gp in
tumors and the opposite in adjacent colons (Figures 4C,D).
Discussion
NPC1L1 protein, a protein of more than 1,300 amino
acids, has 13 transmembrane domains and 5 of them con-
stitute a sterol-sensing domain [5,25]. Its major function is
a sterol transporter [5,8,15]. The NPC1L1 inhibitor, ezeti-
mibe, began to be used to lower serum cholesterol in
clinic but this has caused the great debate [6,7]. Biological
scientists and clinical doctors raised the concern about its
role in cancer recently.
Here, we testified that NPC1L1−/− mice were resistant
to colitis-associated tumorigenesis. At different time
points, NPC1L1−/− mice consistently had much fewer
colorectal tumors than WT mice (Figures 1C-G). The
ratio of malignant tumor/tumor in NPC1L1−/− at week
20 was also significantly lower than in WT (Figure 2D).P53
Adjacent Colon Tumor





















































































Figure 4 Proteins (p53, β-catenin, TGF-β and p-gp) associated with tu
and p53 of adjacent colons and tumors were assayed by western blot. Rela
actin, respectively. (C, D) TGF-β and p-gp of adjacent colons and tumors w
were analyzed and normalized to α-tubulin, respectively. *p < 0.05, **p < 0.0To explore clues to possible mechanisms of NPC1L1
knockout protecting mice against colitis-associated tumori-
genesis, NPC1L1 protein in colorectal mucous membranes
and tumors was assayed. Western blot showed that
NPC1L1 protein level was high in small intestines while it
was undetectable in colorectal mucous membranes or colo-
rectal tumors (Figure 3A). It is reported that NPC1L1
mRNA was highly expressed in liver and small intestines of
humans and only in small intestines of mice [8,14]. In the
colon, its mRNA is very low [8,14]. Based on these results,
NPC1L1 knockout reducing colitis-associated tumorigen-
esis is unlikely due to NPC1L1 ablation in colorectal mu-
cous membranes.
NPC1L1 major function is a sterol transporter in small
intestines and livers to modulate lipid homeostasis
[8,15]. Plasma lipid, especially cholesterol, is strongly
and positively associated with colorectal cancer and pro-
motes colitis-associated tumorigenesis in mice [1-4,16].
Therefore, plasma lipid was assayed. NPC1L1 knockout
significantly decreased plasma lipid, especially choles-
terol (Figure 3B). Hence, plasma lipid, especially choles-
terol, may be involved in the mechanism of NPC1L1
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morigenesis were assayed by western blot. (A, B) Protein β-catenin
tive quantities of β-catenin and p53 were analyzed and normalized to
ere assayed by western blot. Relative quantities of TGF-β and p-gp
1, #p >0.05, ##p =0.08.
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tumorigenesis through inflammation [16]. To explore
whether inflammation was involved in NPC1L1 knockout
reducing colitis-associated tumorigenesis, the intestinal in-
flammation was scored. NPC1L1 knockout significantly
decreased intestinal inflammation scores (Figure 3C). It
significantly decreased p-c-Jun, p-ERK and caspase-1 p20,
three inflammatory markers [17-20], in colorectal tumors
(Figure 3D). Those suggested that NPC1L1 knockout re-
duced sensitivity to inflammatory agents. Therefore,
NPC1L1 knockout decreasing plasma lipid, especially
cholesterol, to reduce inflammation may be involved in
the mechanism.
Lymphadenectasis also indicates inflammatory activity,
somehow, because inflammation and cancer are main
causes of lymphadenectasis [10,23,24]. H&E staining
showed that none of enlarged lymph nodes were caused
by metastatic cancer (Figure 3F). Therefore, NPC1L1−/−
mice having fewer enlarged lymph nodes (Figure 3E,
Table 2) also suggests NPC1L1−/− mice may be hyposen-
sitive to inflammatory agent.
To explore clues to the detail mechanisms of NPC1L1
knockout reducing colitis-associated tumorigenesis, β-
catenin, p-c-Jun, p-ERK, TGF-β, p-gp and p53 were
assayed.
NPC1L1 knockout significantly decreased β-catenin,
p-c-Jun and p-ERK in tumors. Increasing β-catenin, c-
Jun phosphorylation and ERK activation were reported
to promote colon tumorigenesis [10,11,21,22]. It is lo-
gical to consider that β-catenin, p-c-Jun and p-ERK may
be involved in the mechanism of NPC1L1 knockout pro-
tecting mice from colitis-associated tumorigenesis.
TGF-β and p-gp also play a positive role during intes-
tinal tumorigenesis [26,27]. Interestingly, NPC1L1 knock-
out dramatically increased active TGF-β and p-gp in
tumor but dramatically decreased them in adjacent
colon. On the contrary, NPC1L1 knockout decreased
TGF-β precursor in tumor and increased it in adjacent
colon (Figure 4B). It seems that TGF-β and p-gp might
play complicated roles in mechanisms.
Protein p53, the most famous tumor suppressor pro-
tein, is involved in colorectal tumorigenesis and lipid
metabolism [28,29]. Beyond our expectation, NPC1L1
knockout did not significantly change its expression ei-
ther in adjacent colon or in tumor.
Conclusions
NPC1L1 knockout in mice protects mice against colitis-
associate colorectal tumorigenesis. This indicates NPC1L1
inhibitor might be used to protect against CRC as well as
to lower cholesterol. Since NPC1L1 genotype is different
amongst people [30], our results may also contribute to ex-
plain differences in colorectal cancer susceptibility amongst
people. NPC1L1 protein was undetectable in colorectalmucous membranes or tumors. NPC1L1 knockout de-
creased plasma lipid, especially cholesterol and reduced
sensitivity to inflammatory agents. It is reported that
lipid, especially cholesterol, promoted colitis-associated
tumorigenesis through inflammation [16]. Therefore,
NPC1L1 knockout decreasing plasma lipid, especially
cholesterol, to reduce inflammation may be involved in
the mechanism. NPC1L1 knockout decreasing β-catenin,
p-c-Jun and p-ERK may also be involved in the mechan-
ism. Further experiments are needed to clarify the compli-
cated mechanism.
Additional file
Additional file 1: Figure S1. Clinic parameters. (A) Body weight of WT
began to decrease earlier than that of NPC1L1-/-. (When mice were
injected with AOM, they were weighed and this body weight was
regarded as original body weight). (B) Epididymal fat (EPI) weight/body
weight ratio of WT began to decrease earlier than that of NPC1L1-/-.
(*p<0.05, #p>0.05). These suggested WT might have cachexia what might
be caused by tumors earlier than NPC1L1-/-. (C) WT mice had higher ratio
of liver weight/body weight than NPC1L1-/- mice as we previously
described (#p=0.076, *p<0.05, **p<0.01 compared to WT).
(D) WT mice had heavier spleen than NPC1L1-/- mice and this might be
due to anemia caused by DSS-induced colitis or tumor (#:p=0.060,
##p=0.079, *p<0.05, **p<0.01 compared to WT). This suggested that
WT might have more tumors and/or more serous inflammation than
NPC1L1-/-. (E) Spleen, lung and kidney. Tumor wasn’t found either in WT
group or in NPC1L1-/- group.
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